| [Flash Point] 110 | |
| [Fire Fighting] Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire. | |
| [Ingestion] Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended. | |
| [Inhalation] If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention. | |
| [Skin] Remove contaminated clothing. Wash exposed area with soap and water. If symptoms persist, seek medical attention. Launder clothing before reuse. | |
| [Eyes] If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention. | |
| [Storage] Clofibrate liquid-filled capsules should be stored in well-closed, light-resistant containers, at a temperature less than 40C. Preferably at 15-30C; freezing of the liquid-filled capsules should be avoided. | |
| [Handling] All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood. | |
| [Skin] Various rashes and alopecia have been reported. | |
| [Ingestion] Ausea, vomiting, constipation, dyspepsia, diarrhea, and flatulence occur transiently in approximately 10% of patients. Epigastric pain has been reported as a frequent side effect and cholelithiasis is increased. | |
| [Personal Protection] Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots. | |
| [Respirators] Use NIOSH/MSHA approved respirator appropriate for exposure of concern. | |
| [Exposure Effects] with therapeutic use - fatigue, weakness, drowsiness, dizziness, and headache have been reported during clofibrate therapy. Clofibrate and Fenofibrate are classified as FDA Pregnancy Category C. | |
| [Appearance] Oil. Faint characteristic odor. | |
| [Solubility in water] insoluble | |
| [Boiling Point] 148 | |
| [Density] 1.138-1.144 g/cm3 (20 C) | |
| [Usage] Agent to lower plasma very-low-density-lipoprotein concn, agent to lower concn of plasma triglycerides. | |
| [Refractive Index] 1.505 (19 C) | |
| [Product Name] Ethyl 2-(4-chlorophenoxy)-2-methylpropionate | |
| [Synonyms] 2-(P-chlorophenoxy)-2-methylpropionic*acid ethyl Antilipid Ateculon Ethyl 2-(4-chlorophenoxy)-2-methylpropionate Ethyl clofibrate Phenoxyisobutyricacidethylester | |
| [CAS] "CASEN_637-07-0.htm">637-07-0 | |
| [Formula] C12H15ClO3 | |
| [Molecular Weight] 242.7 | |
| [EINECS] 211-277-4 | |
| [RTECS] UE9480000 | |
| [RTECS Class] Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data | |
| [Merck] 12,2436 | |
| [Beilstein/Gmelin] 1913459 | |
| [Beilstein Reference] 4-06-00-00851 | |
| [Small spills/leaks] Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces. | |
| [Stability] Sensitive to oxidation and light; easily hydrolyzed. | |
| [Incompatibilities] Strong oxidizing agents. |
Print